Premium
S4–01–04: Abeta–antibodies in serum and CSF as potential marker of biological activity in AD
Author(s) -
Du Yansheng,
Wei Xing,
Zhao Liming,
Dodel Richard,
Hampel Harald,
Farlow Martin
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.266
Subject(s) - autoantibody , antibody , biomarker , immunology , pathogenesis , medicine , subclass , disease , titer , biology , biochemistry
Background: Naturally occurring autoantibodies against amyloid (A ) peptide have been identified in both CSF and serum from normals and patients with Alzheimer’s disease (AD). However, the role of these antibodies play in AD pathogenesis and whether they can used as biomarkers for AD remain unclear. Objective(s): Determining whether autoantibodies against A can be used for diagnosis or treatment in AD. Methods: Autoantibodies against A in human IVIG product were purified by affinity columns and injected into APP transgenic mice in different doses. The CSF and plasma levels of A were analyzed using ELISA to determine the relationship of antibody levels and A levels. Additionally, a study was performed to investigate the correlation between CSF and serum levels of autoantibodies and A in humans. Result: Higher doses of autoantibodies against Ab were associated with increased plasma and decreased CSF levels of A . However, lower doses of these antibodies had little effects on A levels in either plasma or CSF. Moreover, human CSF and serum autoantibodies against A titers also did not correlate to the Ab levels. Conclusions: Human naturally occurring autoantibodies against A can efficiently raise plasma A levels from hypothesized brain sources. However, since low doses of these antibodies had little effect on A levels, they may not be useful as an effective biomarker in early diagnosis and follow-up of AD. These antibodies appear to have potential as an immunotherapeutic treatment for AD.